Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Other Non-Cash Items

Last Annual Value

3.99M

3-Year CAGR

22%

5-Year CAGR

113%

10-Year CAGR

96%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Other Non-Cash Items

NTRB · NASDAQ
CompanyOther Non-Cash Items
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
3.99M
78.4%12.4%73.9% 
-1.95M
N/AN/AN/A
-41.84M
N/AN/AN/A
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
-3.33M
N/AN/AN/A
1.03M
-1.2%-6.0%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
3.53M
-45.9%15.4%N/A
804.94K
N/A-4.2%N/A
21.92M
112.0%73.9%102.0%
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
-2.94M
N/AN/AN/A
IMA logo
ImageneBio Inc
NASDAQ:IMA
8.02M
-4.0%46.9%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
497.00K
-1.7%-43.5%19.3%
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15